全球水产养殖疫苗市场-2022-2029
市场调查报告书
商品编码
1129258

全球水产养殖疫苗市场-2022-2029

Global Aquaculture Vaccines Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

水产养殖疫苗的创新有望推动市场增长。

随着技术的进步,Elanco 研发出一种新的鲑鱼病毒疫苗,即核酸疫苗。这些疫苗接种提供了一种更有效的方法来保护鲑鱼免受病毒感染。核酸疫苗仅具有导致抗原形成的病原体的相关遗传成分。这些元素被放入称为质粒的环状核酸结构中,当注射到肌肉中时,它会指示细胞以模拟对真实感染的免疫反应的方式製造抗原。核酸疫苗只含有一小部分病毒,因此没有传播疾病的风险。

此外,根据全球海鲜联盟的说法,植物性鱼类疫苗有可能为养殖鱼类提供低成本、高安全性和有效的保护。疫苗植物工厂的可行性、有效性和安全性已在多项临床前和临床研究中得到证明。基于植物的平台为重组亚单位疫苗提供了引人注目的优势。植物性疫苗不存在活疫苗的安全问题。与基于哺乳动物的生产系统相比,在基于植物的系统中没有发现不需要或有害的成分,例如细菌毒素或酵母衍生的不需要的蛋白质。此外,植物衍生系统与天然衍生系统一样,具有很高的生物合成能力,可以增强疫苗的免疫原性。由植物製成的口服疫苗是最好的。製造过程简单,无需额外的医疗设备进行注射。高纯度植物性疫苗提高了疫苗接种的便利性,增强了免疫反应。当口服疫苗抗原时,它们会通过胃并被肠道吸收,从而引发免疫反应。可以通过低成本、安全和高效的植物性疫苗接种来保护养殖鱼类。由于这些原因,预计市场在预测期内将扩大。

约束

水产养殖疫苗生产和批准的严格监管政策以及復杂的疫苗开发方法可能是预测期内阻碍市场增长的因素之一。

行业分析

水产养殖疫苗市场根据供应链分析、价格分析等各种行业因素对市场进行深入分析。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了积极影响。水产养殖者正在实施保守的养殖策略,以减少接触 COVID-19 危害并防止价格下跌造成的经济损失,预计 2020 年总产量将下降 1.3%。这些数字未经证实,但这将标誌着近 60 年来全球水产养殖产量首次出现年度下降,与前几年 4-5% 的稳定增长率大相径庭。然而,由于生长速度、生产週期长度、市场需求等方面的差异,影响的强度和生产者的反应因物种而异。同样重要的是要了解,对于一些养殖物种,在最初的生产中断后市场供应可能需要一段时间才能改变。此外,由于劳动力减少以及 COVID-19 传染病疫苗生产趋势的变化,水产养殖疫苗生产的减少也对市场产生了影响。因此,从上述描述来看,随着经济活动的恢復,预计市场将受到影响并迅速获得牵引力。

全球水产养殖疫苗市场报告提供大约 45 多个市场数据表、40 多个数字和 200 页结构。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 水产养殖疫苗的创新有望推动市场增长。
    • 限制因素
      • 预计水产养殖疫苗生产和审批方面的严格监管政策将阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 减毒活疫苗
  • 灭活□□疫苗
  • 亚单位疫苗
  • DNA 疫苗
  • 重组疫苗

第 8 章给药途径

  • 口语
  • 注入
  • 沉浸式
  • 其他

第 9 章按应用程序

  • 细菌感染
  • 病毒感染
  • 寄生虫感染
  • 其他

第 10 章按鱼类分类

  • 罗非鱼
  • 鳟鱼
  • 三文鱼
  • 鲈鱼
  • 皮脂
  • 其他

第 11 章,最终用户

  • 兽医医院
  • 兽医医院
  • 其他

第 12 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 13 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 14 章公司简介

  • 默克公司
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Tecnovax
  • Hipra
  • Zoetis LLC
  • Phibro Animal Health Corporation
  • Elanco
  • KBNP, INC.
  • Kyoto Biken Laboratories, Inc.
  • Veterquimica S.A.
  • Virbac S.A.

第 15 章全球水产养殖疫苗市场-DataM

简介目录
Product Code: DMVH5834

Market Overview

Aquaculture Vaccines Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

A protective immune response is created in an animal during vaccination through administering vaccinations. Antigens from pathogenic organisms that have been turned non-pathogenic through various processes are used in vaccines to stimulate the animal's immune system and raise its resistance to disease when pathogens are met naturally. Vaccination is an easy, effective and preventive method of protecting fish from diseases.

Market Dynamics

Innovation in aquaculture vaccines is expected to drive market growth.

Due to its technological advancements, Elanco has created a new class of salmon virus vaccinations known as nucleic acid vaccines. These immunizations provide a more focused method for protecting salmon from viral infections. Only the relevant genetic elements of the pathogen that cause the formation of an antigen are present in nucleic acid vaccines. These elements are placed into a plasmid, a circular nucleic acid structure, which, when injected into a muscle, instructs cells to manufacture antigens in a manner that resembles the immunological response to a genuine infection. Nucleic acid vaccines do not risk spreading the illness because they only contain a small portion of the virus.

Moreover, according to the global seafood alliance, Plant-based fish vaccines could provide low-cost, high safety and effective protection for farmed fish species. The viability, effectiveness, and safety of plant factories for vaccines have been demonstrated in several pre-clinical and clinical trials. A plant-based platform offers attractive benefits for recombinant subunit vaccines. The safety issues with live vaccinations are not present with plant-based vaccines. In contrast to mammalian-based production systems, undesirable or harmful components, such as bacterial toxins and undesired proteins from yeast, have not been discovered in plant-derived systems. Like naturally occurring systems, plant-based systems have a high capacity for biosynthesis, which boosts the immunogenicity of vaccines. Oral vaccinations made from plants are the best. The production procedure is straightforward, and injection does not require the use of any additional medical equipment. High purity plant-based vaccines make vaccination more convenient and boost immune responses. When vaccine antigens are consumed orally, they pass past the stomach and are absorbed in the intestine, triggering immunological reactions. Fish raised on farms could be protected with low-cost, highly safe, and efficient plant-based vaccinations. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint

Stringent regulatory policies for the manufacturing and approving of aquaculture vaccines and complicated vaccine development approaches are some factors the market is expected to hamper the market growth in the forecast period.

Industry Analysis

The aquaculture vaccines market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted healthcare systems and the market. Aquaculture farmers have implemented conservative stocking strategies to lessen their exposure to COVID-19 hazards and prevent financial losses in the face of declining pricing, which is expected to result in a 1.3 percent decrease in total output in 2020. Although this number hasn't been verified, it would represent the first yearly fall in worldwide aquaculture production in nearly 60 years and a striking break from the steady 4-5 percent pace of growth seen over the past few years. However, due to the variations in growth rates, lengths of production cycles, and market demands, the impact's intensity and the producers' response have varied greatly depending on the species. It's also crucial to understand that market supply for some aquacultured species may take some time to change after early production process disturbances. Additionally, the decrease in aquaculture vaccine manufacturing caused by the reduced workforce combined with changing trends to produce a vaccine for COVID-19 infection has also impacted the market. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Inactivated Vaccines segment is expected to hold the largest market share in aquaculture vaccines market

The inactivated vaccines segment is expected to dominate in 2021. The segment benefits because the process of killing a pathogen that is cultivated and then turned into a vaccine is used to create inactivated vaccinations, also referred to as killed vaccines. These vaccines are the ones that are typically used to prevent various bacterial and viral infections. Moreover, Strong immune responses are produced by inactivated vaccines by keeping the inactive genetic component, and the virus surface exposed antigens are crucial for a strong immune response. Additionally, since inactivated vaccination does not persist in the environment or in the fish that have received it, it is safe, which increases demand. Although regular dosages are necessary, there is very little possibility of a pathogen returning or interfering with the system. One of the most widely used vaccines that are also legally and commercially available is inactivated vaccines. Certain vaccines are available for disorders, including infectious salmon anemia and infectious pancreatic virus, among others. Therefore, it has increased the demand for inactivated aquaculture vaccines. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global aquaculture vaccines market

In 2021, North America accounted for the highest revenue share. The market's increasing research and development investment, government support for aquaculture vaccine development, product launches and acquisitions by the key regional players are some of the factors the market is expected to boost in the forecast period. For instance, the University of Florida received planting solutions grant from the Foundation for Food & Agriculture Research (FFAR) in February 2021 for around USD 790,326. The goal of this investment was to aid in the creation of a vaccine delivery method that will stop the tilapia lake virus and other diseases from spreading inside the aquaculture sector. Moreover, in July 2020, Zoetis acquired Fish Vet Group from Benchmark Holdings, PLC. This added to the company's Pharmaq business, which is involved in fish vaccines and services. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the aquaculture vaccines market are Merck & Co., Inc., Tecnovax, Hipra, Zoetis LLC, Phibro Animal Health Corporation, Elanco, KBNP, INC., Kyoto Biken Laboratories, Inc., Veterquimica S.A., Virbac S.A.

Merck & Co., Inc.:

Overview:

Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biological therapies and animal health products. The company's operations are principally managed on a product basis and include two operating segments, the pharmaceutical and animal health segments, both reportable. The company offers vaccinations, poultry, cattle, and aquaculture products, among other animal health items. Merck provides managed healthcare services to hospitals, government organizations, wholesalers, retailers, and hospitals. It also provides veterinarians, distributors, and animal producers with animal health products. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Outside of North America and Canada, Merck is known as MSD, and its global headquarters are in Kenilworth, New Jersey.

roduct Portfolio:

AQUAVAC IridoV: AQUAVAC IridoV, an oil-adjuvanted vaccine, is administered intraperitoneally as a single-injection dose to fish weighing no less than 5 grams. Fish susceptible to this disease include species such as Asian seabass, grouper, pompano and Japanese yellowtail.

The global aquaculture vaccines market report would provide an access to an approx. 45+market data table, 40+figures and 200pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Innovation in aquaculture vaccines is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent regulatory policies for the manufacturing and approving of aquaculture vaccines are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Attenuated Live Vaccines*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Inactivated Vaccines
  • 7.4. Subunit Vaccines
  • 7.5. DNA Vaccines
  • 7.6. Recombinant Vaccines

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Injected
  • 8.4. Immersion
  • 8.5. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Bacterial Infection*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Viral Infection
  • 9.4. Parasitic Infection
  • 9.5. Others

10. By Species Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 10.1.2. Market Attractiveness Index, By Species Type Segment
  • 10.2. Tilapia*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Trout
  • 10.4. Salmon
  • 10.5. Seabass
  • 10.6. Seabream
  • 10.7. Others

11. By End user

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.1.2. Market Attractiveness Index, By End user Segment
  • 11.2. Veterinary Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Veterinary Clinics
  • 11.4. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. Merck & Co., Inc.*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Tecnovax
  • 14.3. Hipra
  • 14.4. Zoetis LLC
  • 14.5. Phibro Animal Health Corporation
  • 14.6. Elanco
  • 14.7. KBNP, INC.
  • 14.8. Kyoto Biken Laboratories, Inc.
  • 14.9. Veterquimica S.A.
  • 14.10. Virbac S.A.

LIST NOT EXHAUSTIVE

15. Global Aquaculture Vaccines Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us